NCT05905341 2023-11-08
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
Pfizer
Medical College of Wisconsin
University of California, San Francisco
University of Wisconsin, Madison